Newsroom

LATEST NEWS AND EVENTS

EANM response to ASTRO’s framework for trainees

A major component to successfully establish radioligand therapy

European Commission approves Pluvicto™

Novel PET Agent to Identify Patients for Targeted Therapies

New PET Tracer Shows Promise for NENs

What are Radiotheranostics for Cancer Care?

Dr Acosta’s testimonial : A journey living with prostate cancer

The Oncidium foundation is hiring!

36th Brazilian Congress of Nuclear Medicine

Novel radiopharmaceutical pair detects and treats melanoma

SNMMI Abstract of the Year 2022

6th Theranostics World Congress

Theranostics in the Arab World

Tackle Cancer Challenge, A Huge Thank You!

Cu-64-SAR-Bombesin PET-CT imaging for metastatic breast cancer

Tackle Cancer Challenge: It’s a wrap!

May 30 – Webinar – PSMA PET/CT Beyond the Images

ANZSNM 2022 – Brisbane, Australia

8th International Symposium on Medical Radioisotopes

The Tackle Cancer Challenge starts today!

Join the Tackle Cancer Challenge!

The Second Edition of Radiotheranostics Today is out!

Lu-177-PSMA-617 approved by FDA for prostate cancer patients

Novel Radioligand Proven Superior for Metastatic Prostate Cancer

Estimate the anticipated benefit from Lutetium-177-DOTATATE

Theranostics: A Smart Bomb for Cancer

Encouraging Early Results for Prostate Cancer Screening

Radiotheranostics Today by the Oncidium foundation

Get more insight from the NOBLE Registry Website

Q&A: How a new imaging tool helps to better stage prostate cancer

Scandium radionuclides for theranostic applications

Emirates International Virtual Conference in Nuclear Medicine

Patient Management with Lu-177–PSMA-617 in the Clinic

Health Policy Partnership Framework

PSMA Theranostics: Current Landscape and Future Outlook

The Rising Role of Radiotheranostics

Lu-177-PSMA-617A Added to Standard Therapy

Theranostic Approach in Breast Cancer

FDA for Lu-177-PSMA-617 for mCRPC treatment

Global Nuclear Medicine Market 2013-2025

Drugmakers push into radio pharmaceuticals

NOBLE: Tc-99m-iPSMA SPECT shows promising results

Asco 2021 justifies Novartis’s radioligand Vision

Theranostics: Reimagining the standard of care

EANM position paper on the role of radiobiology in nuclear medicine

Travel cards could help radiopharma patients avoid delays

PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC

XXII Congreso Argentino de Medicina Nuclear – Virtual Edition

Noble Registry – iPSMA SPECT Imaging for Prostate Cancer

Doctor, What is Neuroendocrine Cancer?

How Nuclear Technology can Beat Cancer

Seeing Cancer Cells, Killing Cancer Cells

Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC

How PRRT can Improve Care for Neuroendocrine Tumor Patients

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

Real-world data analysis of efficacy and survival after Lu-177 PSMA

What is in the pipeline for nuclear medicine, globally?

Oncidium foundation welcomes it’s Turkish Ambassador

Oncidium foundation is a corporate member of the SNMMI Value Initiative

Joint Radionuclide Therapy-Immunotherapy Approach Effective in Prostate Cancer Model

New Theranostic Approach reduces tumor volume and increases survival in NET’s study

Another achievement to bring Radiotheranostics forward

NET Patient Testimonial, how PRRT saved Tom’s life

Diagnostic accuracy of F-18-PSMA-1007-PET/CT imaging for prostate carcinoma

IPET 2020 – all you need to know about Theranostics

Radiopharmaceuticals Emerging as New Cancer Therapy

October Rose – Breast Cancer Awareness Month

EANM ’20 – Let’s talk Radiotheranostics!

Nuclear Medicine and Molecular Imaging Week: October 4-10, 2020

First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients

IAEA activities on Cu-67, Re-186, Sc-47 Theranostic radionuclides and Radiopharmaceuticals

The Role of Ga-68-FAPI PET/CT for Malignancies of the Lower GI Tract

Cancer awareness month – September, don’t forget to remember

First patients dosed in clinical trial of novel lung and ovarian cancer theranostic

Sirtex Medical and China Grand Pharmaceutical milestone

Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer

Astatine is a chemistry puzzle that shows anticancer promise

This is not a simple flower, this is an Oncidium

Webinar Theranostics and PET Imaging Diagnostics

Theranostics continue to gain momentum

CONNECT WITH US

Oncidium foundation · 3 days ago
@OncidiumFoundat

A warm welcome to Dr. Solange Amorim Nogueira (Sao Paulo) and Dr. Adelina Sanches (Salvador), two great new additions to the fantastic team of Oncidium foundation Ambassadors in Brazil! 🤩
Follow their news 👉 https://t.co/WadOa4IvCC
#theranostics #nuclearmedicine #cancercare https://t.co/3NdFKBozKA

View on Twitter

Oncidium foundation · 1 week ago
@OncidiumFoundat

Welcome Claire Woodthorpe & Dr. Vercher Conejero as our first two Ambassadors in Barcelona, Spain🤩.They will be working on awareness, research & access projects & bringing a Spanish and European perspective opportunities & challenges regarding #radiotheranostics for #cancercare https://t.co/kA4O4tK7wJ

View on Twitter

Oncidium foundation · 2 weeks ago
@OncidiumFoundat

It's today! The Michal Hofman Masterclass: #PSMA a new era #prostatecancer.
Registration link 👉 https://t.co/iZ2t16Y4eR
#radiotheranostics #theranostics #cancercare #nuclearmedicine #precisioncology #accesseducationhope https://t.co/SWLke3tsC7

View on Twitter

UroTeragLATAM@UroTeragLATAM
Masterclass: PSMA - a new era in prostate cancer por @DrMHofman de @pros_tic.

Agradecemos a @Bayer4CropsAR @OncidiumFoundat @mimsoftware @nmwlatam IMAXE, Tecnonuclear.

Aval académico: @aaoncoclinica @AAByMN1 @SauUrologia @SocArgRad

Inscripciones: https://t.co/sV9HVg2sV2

🧵 https://t.co/sbt36guDWh

Oncidium foundation · 2 weeks ago
@OncidiumFoundat

We strive to make #radiotheranostics available to as many people worldwide as possible. Closing the care gap and creating a world where patients have equitable access to treatment and clinical trials is part of our core mission. #OncidiumFoundation https://t.co/dUX4ZThvzh

View on Twitter